• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The present invention relates to a cosmetic or dermatological or nutritional composition comprising an isotonic and osmotic electrolyte solution, characterized in that said isotonic electrolyte solution consists of: 74% by weight of a source water, relative to the total weight of the isotonic electrolyte solution, and 26% by weight of seawater, relative to the total weight of the isotonic electrolyte solution. The present invention also relates to the use of an osmotic isotonic electrolyte solution as a cell living medium as described above in a cosmetic or dermatological or nutritional composition and on a process for preparing such a solution.
    公开号:FR3041253A1
    申请号:FR1558879
    申请日:2015-09-21
    公开日:2017-03-24
    发明作者:Fabienne Bresdin
    申请人:Fabienne Bresdin；
    IPC主号:
    专利说明:

    FIELD OF THE INVENTION
    The present invention relates to a cosmetic or dermatological or nutritional composition being or comprising an isotonic electrolyte solution, and a cosmetic or dermatological or nutritional care method. The present invention also relates to the use of the isotonic electrolyte solution as an active solvent and a method of preparing the isotonic electrolyte solution.
    PRIOR ART
    The skin contains about 70% water, about 15% of all that is in the human body. Its fundamental role is to maintain the balance of the indoor environment, to ensure homeostasis and eliminate toxins.
    The principle of homeostasis governs biological exchanges and requires that a liquid to be biocompatible best respects the internal environment of the cells. The maintenance of homeostasis is ensured by a set of complex mechanisms: maintenance of the osmotic pressure, the partial pressure of 02 and CO2, the temperature, the pH, etc. Respect for homeostasis is an important condition for the health of the body and the skin: it is a dynamic equilibrium that must be constantly restored to the changes due to the environment and metabolism. Water is the major component of cosmetic or dermatological formulations for the care of the skin. The water used in formulation is generally treated, neutral and demineralized water which is then reduced to the simple role of solvent.
    There is therefore a need in the cosmetic, dermatological or nutritional fields for an isotonic active solvent in perfect physiological balance with the inner environment of the skin.
    SUMMARY OF THE INVENTION
    In the context of the present invention, the inventors have discovered an isotonic electrolyte solution in perfect equilibrium with the intercellular medium or the blood plasma. It contains the main mineral salts and trace elements in ionic form, that is to say all the vital mineral salts and all trace elements naturally occurring in human blood plasma. In addition, it has an important buffering capacity, a pH between 7.9 and 8.3 and a saline concentration of 0.9% (i.e. total concentration of mineral salts and trace elements of the electrolyte solution and equivalent to that of human plasma). The buffering power ensures the acid-base balance of the body. When this isotonic electrolyte solution is used in place of the demineralized water in a formulation, the solvent becomes active.
    In a first aspect, the present invention therefore relates to a cosmetic or dermatological or nutritional composition comprising an isotonic electrolyte solution, characterized in that said isotonic electrolyte solution consists of: 74% by weight of a source water, relative to the weight total of the isotonic electrolyte solution, and 26% by weight of seawater, relative to the total weight of the isotonic electrolyte solution.
    In a second aspect, the invention relates to the use of an isotonic electrolyte solution as defined above as an active solvent in a cosmetic or dermatological or nutritional composition.
    In a third aspect, the invention relates to a method of cosmetic or dermatological care comprising the administration, preferably topical or orally, of a cosmetic or dermatological or nutritional composition as defined above.
    In a fourth aspect, the invention relates to a method for preparing an isotonic electrolyte solution as defined above, comprising the following steps: a) mixing 74% by weight of the source water and 26% by weight seawater weight, based on the total weight of the isotonic electrolyte solution; b) sterilizing the resulting mixture, preferably by cold processes, more preferably by 0.2 micron microfiltration or by reverse osmosis; c) optionally conditioning the solution obtained, preferably in a vacuum bag, ampoules or flasks.
    DEFINITIONS
    For the purposes of the invention, the term "isotonic electrolyte solution" means a solution that has substantially the same ionic concentration as the body's fluids, in particular blood plasma and the intracellular medium. Isotonicity is characterized by the presence of all the ions in equivalent concentration of that of the blood plasma or the intracellular medium.
    By "source water", within the meaning of the invention means a water from groundwater, preferably naturally suitable for human consumption.
    By "seawater", within the meaning of the invention, is meant water from the seas and oceans of the Earth.
    DETAILED DESCRIPTION OF THE INVENTION
    According to a first aspect, the present invention relates to a cosmetic or dermatological or nutritional composition comprising an isotonic electrolyte solution, characterized in that said isotonic electrolyte solution consists of: 74% by weight of a source water, relative to the total weight of the isotonic electrolyte solution, and 26% by weight of seawater, relative to the total weight of the isotonic electrolyte solution.
    The solution according to the invention has the same ionic characteristics as the human intercellular medium or the blood plasma.
    In particular, the solution according to the invention comprises, in a constant manner, the following ions: chloride (CT) at a concentration of between 3500 and 4000 mg / l, advantageously between 3700 and 3900 mg / l, more advantageously 3890 mg / l; calcium (Ca 2+) at a concentration of between 100 and 150 mg / L, preferably between 110 and 150 mg / L, more preferably 138 mg / L; magnesium (Mg 2+) at a concentration of between 250 and 400 mg / L, preferably between 300 and 350 mg / L, more preferably 346 mg / L; Potassium (K +) at a concentration of between 100 and 200 mg / L, advantageously between 150 and 170 mg / L, more advantageously 150 mg / L; and
    Sodium (Na +) at a concentration of between 2500 and 3500 mg / L, advantageously between 2700 and 3500 mg / L, more preferably 2783 mg / L.
    The solution according to the invention advantageously has a constant total concentration of chloride, calcium, magnesium, potassium and sodium ions of 7.31 g / l.
    The solution according to the invention advantageously has a conductivity of between 1000 and 1500 Ω ^ .αη'1, advantageously of 1115 and 1130 ff'.cm'1, more advantageously of 1122 ff'.cm'1.
    The following Table 1 compares the ionic composition of a solution according to the invention and that of the blood plasma:
    Table 1.
    * Normal values - Source: Larousse Encyclopedia: "blood"
    The solution according to the invention is therefore an isotonic solution with respect to human blood plasma. The source water which composes the solution according to the invention advantageously comprises the following ions, in a constant manner: chloride (C1 ') at a concentration of between 100 and 200 mg / l, advantageously between 160 and 200 mg / l, more advantageously 174 mg / L; calcium (Ca 2+) at a concentration of between 30 and 60 mg / L, preferably between 35 and 45 mg / L, more preferably 40 mg / L; magnesium (Mg 2+) at a concentration of between 15 and 35 mg / L, preferably between 10 and 20 mg / L, more preferably 18 mg / L;
    Potassium (K +) at a concentration of between 65 and 85 mg / L, advantageously between 70 and 80 mg / L, more preferably 73 mg / L; and Sodium (Na +) at a concentration of between 100 and 200 mg / L, advantageously between 80 and 120 mg / L, more preferably 103 mg / L. The source water advantageously has a constant total concentration of chloride, calcium, magnesium, potassium and sodium ions of 0.41 g / l. The source water advantageously has a conductivity of between 1000 and 1500 Ω '', αη '', advantageously 1115 and 1130 Ω · cm -1, more advantageously 1122 Ω '' cm -1.
    Preferably, the source water is groundwater taken before any treatment. The source water comes from the island of Molène. In particular, spring water is groundwater collected by drilling located on the territory of the municipality of the island of Molène. Such spring water is marketed under the name Eau de Molène®. The seawater which composes the solution according to the invention advantageously comprises the following ions, in a constant manner: chloride (Cf) at a concentration of between 19500 and 19700 mg / l, advantageously between 19550 and 19650 mg / l, more advantageously 19600 mg / L; calcium (Ca 2+) at a concentration of between 350 and 460 mg / L, preferably between 380 and 440 mg / L, more preferably 410 mg / L; magnesium (Mg 2+) at a concentration of between 1250 and 1360 mg / L, preferably between 1290 and 1325 mg / L, more preferably 1315 mg / L; Potassium (K +) at a concentration of between 350 and 460 mg / L, advantageously between 380 and 440 mg / L, more preferably 415 mg / L; and Sodium (Na +) at a concentration of between 11150 and 11350 mg / L, preferably between 11200 and 11300 mg / L, more preferably 11250 mg / L. Seawater advantageously has a constant total concentration of chloride, calcium, magnesium, potassium and sodium ions of 33 g / l. Seawater advantageously has a conductivity of between 53300 and 54000 Q'Vcm -1, advantageously 53500 and 53750 Ω'χιτι'1, more advantageously 53680 Ω '' .cm'1. Seawater is advantageously taken off the northern coast of Brittany, preferably off the island of Molène, 10 to 50 m deep, preferably in calm weather, preferably during rising tides.
    For the purposes of the present invention, the term "quiet time" when the wind force is between 0 and 4 on the Beaufort scale.
    The composition of the various waters and solutions above is analyzed according to the automated colorimetric method according to the ANA-19.MOA.47.Q standard for chloride ions, according to the Flame AAS method and the NF EN ISO 7980 standard for ions. calcium and magnesium, according to the method by AAS flame according to standard NF T90-020 for potassium and sodium ions.
    The conductivity of the various waters and solutions above is measured at 25 ° C according to the probe method according to standard NF EN 27888.
    According to a particular embodiment of the invention, the isotonic electrolyte solution as described above is for non-sterile pharmaceutical use, that is to say that it meets the requirements of the European Pharmacopoeia (8th Edition). pharmaceutical preparations for non - sterile pharmaceutical use (Chapter 5.1.4: Microbiological quality of pharmaceutical preparations and substances for non - sterile pharmaceutical use).
    According to another embodiment of the invention, the isotonic electrolyte solution as described above is sterile. By definition, a sterile product is a product free of viable microorganism (NF EN 556). The theoretical probability of the existence of a revivable micro-organism or a virus must be equal to or less than 10'6. No microorganism should be able to be demonstrated by any method known to those skilled in the art. We generally try to preserve this state by an appropriate conditioning (notion of incontaminable space). This packaging must be waterproof, protective and storable without danger of opening until use.
    When the composition according to the invention is a dermatological or cosmetic nutritional composition, the isotonic electrolyte solution is preferably sterile or for non-sterile pharmaceutical use.
    The composition according to the invention, comprising the isotonic electrolyte solution, is preferably formulated in the form of a solution, oral solution, serum, lotion, spray, milk, oil-in-water emulsion, water-in-oil emulsion or hydrogel.
    Advantageously, the composition according to the invention further comprises at least one active agent and at least one cosmetically or dermatologically acceptable excipient.
    Advantageously, the composition according to the invention is intended to prevent or treat the signs of skin aging, the signs of sensitive or sensitized skin, and / or atopic skin.
    Skin aging can be caused by exposure to UV rays, smoking, stress or exposure to pollution.
    The marks of skin aging that one seeks to fade and / or prevent may be for example wrinkles or fine lines, flaccidity, loss of suppleness, tone, skin firmness, thinner skin or dry skin.
    The skin may be sensitive or sensitized due to external aggression such as the application to the skin of an irritant (eg surfactants, preservatives, soap, hard water with a high concentration of limestone), or because of the environment (such as temperature variations or wind), or because of friction (such as razor burn).
    The signs of sensitive or sensitized skin include the appearance of redness on the skin, tightness, dry skin. Atopy is a hereditary predisposition to respond symptomatically to various allergens. Atopic dermatitis is manifested by skin dryness and inflammatory symptoms including redness, crusts, oozing and itching.
    When the composition according to the invention is a cosmetic or dermatological composition, the isotonic electrolyte solution may be used as a replacement for the demineralized water. Demineralized water is commonly used in cosmetic formulations as a solvent for the aqueous phase; by replacing it with a solution according to the invention, the solvent becomes an active solvent.
    The cosmetic or dermatological composition according to the invention will then have a load of mineral salts and trace elements in equivalence with the human blood plasma. This richness and diversity of mineral salts and trace elements present in perfect physiological balance with the inner environment of the skin makes it possible: to preserve cell life: the solution according to the invention provides a perfect substrate for rebalancing mineral deficiencies and blocking mechanisms of mortality or degeneration; - activate cell renewal and repair mechanisms; and to slow accelerated aging by the emission of free radicals and the low energy yield.
    The isotonic electrolyte solution can also be used as a replacement for the physiological serum in dermatological preparations. The solution according to the invention will then have better tolerance, preserve cell life, stimulate regeneration mechanisms and optimize energy efficiency.
    The solution according to the invention therefore allows applications in cosmetology and dermatology to rebalance the mineral deficiencies of the skin, activate the cell metabolism, preserve cell life thus fight against accelerated aging and revive vital functions.
    When the composition according to the invention is a nutritional composition, it may be a dietary supplement or a drink.
    The isotonic electrolyte solution according to the invention is assimilated by simple osmosis by the body which regulates through this balanced intake of mineral salts and trace elements and whose dosage corresponds to the organic balance.
    The solution according to the invention can act on the deficit field which favors the appearance of diseases. It enables the body to fill its gaps, to find its balance and to face itself to its aggressions. It thus has a preventive action by limiting the risks of disease. It rebalances the human body while presenting no toxicity.
    Today more and more people are deficient in mineral salts and trace elements, and suffer the consequences of an unbalanced ground, acidified by stress or by an inadequate diet, by the taking of excitants, drugs, the lack Exercise: demineralization, chronic fatigue, insomnia ... It is therefore possible to stimulate the vital forces of any organism by regenerating their impoverished interior environment from which the cells feed. The solution according to the invention can allow this stimulation. As soon as this medium regains its vitality, the cells can once again draw from it the elements necessary for their optimum functioning.
    The solution according to the invention therefore allows nutritional applications for anti-aging, rebalancing mineral deficiencies, anti-fatigue, or for recovery after exercise, for any age and without contraindications.
    In a second aspect, the present invention relates to the use of an isotonic electrolyte solution as defined above as an active and osmotic solvent in a cosmetic or dermatological or nutritional composition.
    The cosmetic or dermatological or nutritional composition is advantageously intended to prevent or treat the signs of skin aging, the signs of sensitive or sensitized skin and / or atopic skin.
    In particular, the present invention relates to the use of an isotonic electrolyte solution as defined above to preserve the life of human cells (or cell longevity), promote their multiplication and optimize their mitochondrial activity.
    In a third aspect, the present invention relates to a cosmetic or dermatological care method comprising the administration, preferably topical or oral, of a cosmetic or dermatological composition as defined above.
    Such a composition is advantageously intended to prevent or treat the signs of skin aging, the signs of sensitive or sensitized skin and / or atopic skin.
    In another aspect, the present invention relates to a process for preparing an isotonic electrolyte solution as defined above comprising the following steps: a) mixing 74% by weight of source water and 26% by weight seawater, relative to the total weight of the isotonic aqueous phase; b) sterilizing the resulting mixture, preferably by cold processes, more preferably by 0.2 micron microfiltration or by reverse osmosis; c) optionally, conditioning the solution obtained, preferably in sachet or ampoules or vacuum packs. Source water and seawater are as defined above. Similarly, the isotonic electrolyte solution thus obtained has the same characteristics and properties as that described above.
    In the context of the present invention, the term "sterilization" means a process which renders a product sterile and which makes it possible to maintain this state for a specified period of time (CEN). In other words, it is an operation for eliminating or killing the microorganisms carried by contaminated inert media, the result of this operation being the sterile state (AFNORNF T 72 101).
    The following examples are intended to illustrate the present invention.
    EXAMPLES
    Example 1 Preparation of an Electrolyte Solution According to the Invention
    An electrolyte solution according to the invention is prepared according to the following method: a) the source water Molène Water ® is pumped directly into a borehole and shipped during the day; b) the seawater is pumped with a stainless steel pump off the island of Molène, 30 m deep in calm weather during rising tides and packaged in a stainless steel container or sterile plastic; c) 74% Molène source water and 26% pure seawater are mixed to obtain an isotonic electrolyte solution with osmotic properties (composed of sea water and source water in isotonic mixture); d) the mixture obtained is introduced into a stainless steel tank whose inner surface is covered with a liner; e) microfiltration at 0.2 microns or reverse osmosis; and f) conditioning the solution obtained in a sterile bag or container.
    Example 2 Determination of the Main Ions of an Electrolyte Solution According to the Invention Comparative Analysis with Human Blood Plasma
    The ionic concentrations of the solution thus obtained in Example 1 are measured according to the automated colorimetric method according to the ANA-19.MOA.47.Q standard for the chloride ions, according to the Flame AAS method and the NF EN ISO 7980 standard. for calcium and magnesium ions, according to the AAS flame method according to standard NF T90-020 for potassium and sodium ions.
    Table 1 below compares the different ion concentrations of the electrolyte solution obtained in Example 1 with those of human blood plasma and reconstituted physiological saline:
    * Normal values - Source: Larousse Encyclopedia: "blood"
    Table 1.
    The concentration of the main mineral salts and trace elements of the preparation of the osmotic solution according to the invention is therefore isotonic with respect to that found in human blood plasma. It is therefore an electrolyte solution which has a conductivity similar to that measured in the blood plasma, that is to say its ability to conduct the electric current.
    The mineral salts and the trace elements are in the ionized state and thus electrically charged which gives to their form a bio-bioavailability and allows the osmotic exchanges.
    Example 3 Cell Viability Test - Comparative Analysis Between the Electrolyte Solution According to the Invention and Demineralized Water and Saline
    Purpose of Study
    This study concerns the determination of the in vitro capacity of the solution according to the invention to positively influence cellular proliferation and mitochondrial activation.
    Experimental conditions Materials
    The experimental model is represented by human dermal fibroblasts (ATCC-CRL-2703).
    The proliferation assay is performed using: - Cultured cell cultures for 24 hours, - Cultured cell cultures for 48 hours, - Cell cultures treated for 72 hours. - Cell cultures without any treatment - untreated control, CTR (during the same experimental periods)
    The mitochondrial activation test was performed using: - Cultured cell cultures for 8 hours - Cultured cell cultures for 24 hours - Cultures of cells without any treatment - untreated control, CTR (during the same experimental periods )
    Experimental model preparation and cell exposure
    A preliminary determination of viability, starting from 100%, was performed by the MTT test to select the concentrations of products to be used in the in vitro test. The product did not show a cytotoxic effect and the following concentrations were used to carry out tests: 100%, 50% and 25%. The dilution medium is the cell medium.
    Viability determination and cell proliferation assay were performed in comparison with saline and distilled water.
    MTT Test - Preliminary Viability Test and Cell Proliferation Assay
    Preliminary viability test: the culture medium containing the solution according to the invention at 100% scalar concentrations was added to the wells containing the confluent cells. The cells were exposed to each solution for 24 hours. At the end of the incubation period, MTT staining was performed to evaluate cell viability compared to untreated control (CTR)
    Cell Proliferation Test: The culture medium containing the solution according to the invention at 100% scalar concentrations was added to the wells containing non-confluent cells and previously treated with a serum-free maintenance medium. The cells were exposed to each solution for 24, 48 and 72 hours. At the end of the incubation period, MTT staining was performed to evaluate cell viability compared to untreated control (CTR)
    MTT test: the MTT medium is prepared by adding 15 mg of MTT (3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide) to 30 ml of culture medium. cells to the solution according to the invention, they were washed with 200 μΐ of PB S. After removal of the washing solution, 200 μΐ of MTT medium are added to each culture well and incubated for 4 hours at 37 ° C. C and 5% CO 2 At the end of the incubation period, the MTT medium is removed and 200 μl of MTT solubilization solution (10% Triton X-100 plus 0.1 N HCl in anhydrous isopropanol). ) are added.
    The plate is shaken on a rotating plate for 20 to 30 minutes, to ensure that all crystals are dissolved from the cells and formed a homogeneous solution. The absorbance is measured at 570 nm on a microplate reader, with background reading at 690 nm.
    The results are expressed as a percentage of cell viability compared to a culture of untreated control cells.
    Evaluation of mitochondrial activity At each experimental time, the cells were collected, centrifuged and resuspended in culture medium with JC1 (lpg / ml). After incubation for 15 minutes at 37 ° C., the samples were measured with a Pas III cytofluorometer equipped with a JC 1 reading filter.
    The results were developed to obtain fluorescence values corresponding to different mitochondrial activities. Results
    Cell viability test
    Table 2 below summarizes the results obtained from the cell viability test.
    Table 2.
    The treatment of human dermal fibroblasts with 100% of the solution according to the invention makes it possible to preserve almost all cell life whereas in the other two media the cell death rate reaches 84-86%, that is, to say a cell mortality in almost all.
    This test demonstrates the ability of the osmotic solution according to the invention to maintain cell life with virtually no alteration by probably creating a cellular or physiological environment that recreates a homeostatic balance for the life and survival of skin cells.
    Cell proliferation test
    Table 3 below summarizes the results obtained from the cell proliferation test.
    Table 3.
    The results of these tests demonstrate the ability of the isotonic formula according to the invention to increase cell proliferation, that is to say the regeneration of cells and their multiplication, and this compared to demineralized water and physiological saline.
    This stimulation is significant, as shown in the statistical data in Table 4.:
    Table 4.
    The osmotic solution according to the invention therefore promotes cell renewal.
    Measurement test of mitochondrial activity
    The summary of the results of these tests is given in Table 5 below:
    Table 5.
    The number of active mitochondria in the cells treated with the osmotic solution is not greater than that of the cells treated with the control culture medium. However, while in the control cells, the amount of active mitochondria is constant for 24 hours, in the cells treated with the osmotic solution, there is an increase in the number of active mitochondria over the same period: * + 8.9% between 8H and 24 H in the osmotic solution at the concentration of 100% * + 42.3% between 8H and 24H in the osmotic solution at the concentration of 50% * + 14.5% between 8H and 24H in the osmotic solution at the concentration of 25 %.
    The osmotic solution according to the invention positively modifies the cellular environment by significantly increasing the mitochondrial activity. It has a beneficial effect on the energy efficiency of the cells. The consequences of this beneficial effect are recognized: the cell produces less free radicals and ages less quickly.
    Conclusion
    The treatment of human cells with the osmotic solution according to the invention improves the cellular environment by increasing the lifespan and the cell viability and their capacity for renewal while activating the mitochondrial activity.
    The osmotic solution according to the invention preserves the cell life while the cells do not survive in demineralised water or physiological saline.
    Cell renewal mechanisms are stimulated significantly and more significantly than in the other two environments. Repair and regeneration mechanisms are improved.
    Finally, since the mitochondrial activity is greater, the osmotic solution according to the invention reduces the oxidative stress because the cells age less quickly and produce less free radicals. The osmotic solution according to the osmotic invention is therefore a living medium in physiological equilibrium with the original medium of the cells. It preserves homeostasis. She can replace it.
    权利要求:
    Claims (13)
    [1" id="c-fr-0001]
    1. Cosmetic or dermatological or nutritional composition comprising an isotonic electrolyte solution, characterized in that said isotonic electrolyte solution consists of: 74% by weight of a source water, relative to the total weight of the isotonic electrolyte solution, and % by weight of seawater, relative to the total weight of the isotonic electrolyte solution.
    [2" id="c-fr-0002]
    2. Cosmetic or dermatological or nutritional composition according to claim 1, characterized in that the isotonic electrolyte solution comprises the following ions: chloride (Cl ') at a concentration of between 3500 and 4000 mg / L, advantageously between 3700 and 3900 mg / L, more preferably 3890 mg / L; calcium (Ca 2+) at a concentration of between 100 and 150 mg / L, preferably between 110 and 150 mg / L, more preferably 138 mg / L; magnesium (Mg 2+) at a concentration of between 250 and 400 mg / L, preferably between 300 and 350 mg / L, more preferably 346 mg / L; Potassium (K +) at a concentration of between 100 and 200 mg / L, advantageously between 150 and 170 mg / L, more advantageously 150 mg / L; and Sodium (Na +) at a concentration of between 2500 and 3500 mg / L, advantageously between 2700 and 3500 mg / L, more preferably 2783 mg / L.
    [3" id="c-fr-0003]
    3. Cosmetic or dermatological or nutritional composition according to any one of claims 1 or 2, characterized in that the isotonic electrolyte solution has a total concentration of chloride, calcium, magnesium, potassium and sodium ions of 7.31 g / l.
    [4" id="c-fr-0004]
    4. Cosmetic or dermatological or nutritional composition according to any one of claims 1 to 3, characterized in that the isotonic electrolyte solution has a conductivity of between 1000 and 1500 Ω'.αη'1, preferably 1115 and 1130 Ω'1. .cm'1, more preferably 1122 Ω'1.cm'1.
    [5" id="c-fr-0005]
    5. Cosmetic or dermatological or nutritional composition according to any one of claims 1 to 4, characterized in that the source water comprises the following ions: chloride (Cl ') at a concentration of between 100 and 200 mg / L, advantageously between 160 and 200 mg / l, more advantageously 174 mg / l; calcium (Ca 2+) at a concentration of between 30 and 60 mg / L, preferably between 35 and 45 mg / L, more preferably 40 mg / L; magnesium (Mg 2+) at a concentration of between 15 and 35 mg / L, preferably between 10 and 20 mg / L, more preferably 18 mg / L; Potassium (K-1) at a concentration of between 65 and 85 mg / L, advantageously between 70 and 80 mg / L, more preferably 73 mg / L; and Sodium (Na +) at a concentration of between 100 and 200 mg / L, advantageously between 80 and 120 mg / L, more preferably 103 mg / L.
    [6" id="c-fr-0006]
    6. Cosmetic or dermatological or nutritional composition according to any one of claims 1 to 5, characterized in that the source water is the source water of the island of Molène.
    [7" id="c-fr-0007]
    7. Cosmetic or dermatological or nutritional composition according to any one of claims 1 to 6, characterized in that it is formulated in the form of solution, oral solution, serum, lotion, spray, milk, oil-in-water emulsion, water emulsion in oil or hydrogel.
    [8" id="c-fr-0008]
    8. Cosmetic or dermatological or nutritional composition according to any one of claims 1 to 7, characterized in that it further comprises at least one active agent and at least one cosmetically or dermatologically acceptable excipient.
    [9" id="c-fr-0009]
    9. Cosmetic or dermatological or nutritional composition according to any one of claims 1 to 8, characterized in that. it is intended to revert or treat the signs of skin aging, the signs of sensitive or sensitized skin and / or atopic skin.
    [10" id="c-fr-0010]
    10. Use of an isotonic electrolyte solution as defined in any one of claims 1 to 9 as an active solvent in a cosmetic or dermatological or nutritional composition, advantageously intended to prevent or treat the signs of skin aging, signs of sensitive or sensitized skin and / or atopic skin.
    [11" id="c-fr-0011]
    11. Cosmetic treatment method comprising the administration, preferably topical or oral, of a cosmetic or nutritional composition as defined in any one of claims 1 to 9 and advantageously intended to prevent or treat the signs of skin aging. , and the signs of sensitive or sensitized skin.
    [12" id="c-fr-0012]
    12. Dermatological composition as defined in any one of claims 1 to 9, for use in a dermatological care method, advantageously to prevent or treat the signs of skin aging, the signs of sensitive or sensitized skin and / or atopic skin.
    [13" id="c-fr-0013]
    13. A process for preparing an isotonic electrolyte solution as defined in any one of claims 1 to 9, comprising the following steps: a) mixture of 74% by weight of the source water and 26% by weight seawater, based on the total weight of the isotonic electrolyte solution; b) sterilizing the resulting mixture, preferably by cold processes, more preferably by 0.2 micron microfiltration or by reverse osmosis; c) optionally, conditioning the solution obtained, preferably in sachet or ampoules or vacuum packs.
    类似技术:
    公开号 | 公开日 | 专利标题
    US20070148256A1|2007-06-28|Pharmacologic-functioning water and usage of the same
    FR3041253A1|2017-03-24|USE OF AN OSMOTIC ISOTONIC ELECTROLYTE SOLUTION AS A CELLULAR LIFE MEDIUM IN A COSMETIC, DERMATOLOGICAL OR NUTRITIONAL COMPOSITION
    CN101702880A|2010-05-05|Highly stable electrolytic water with reduced NMR half line width
    Pan et al.2013|Levothyroxine replacement therapy with vitamin E supplementation prevents oxidative stress and cognitive deficit in experimental hypothyroidism
    FR2775898A1|1999-09-17|STRUCTURED WATER IN COSMETIC COMPOSITIONS
    Lopes et al.2020|Carotenoids from cyanobacteria: a biotechnological approach for the topical treatment of psoriasis
    EP1743628A1|2007-01-17|Cosmetic composition containing red algae extract comprising a combination of floridoside and isethionic acid.
    Ziervogel et al.2009|Enzyme activities in the Delaware Estuary affected by elevated suspended sediment load
    Cacciapuoti et al.2020|The role of thermal water in chronic skin diseases management: a review of the literature
    Dakik et al.2020|Discovery of fifteen new geroprotective plant extracts and identification of cellular processes they affect to prolong the chronological lifespan of budding yeast
    Cirilli et al.2021|Role of coenzyme Q10 in health and disease: An update on the last 10 years |
    JP2010155867A|2010-07-15|Pharmacologically functional water and use thereof
    Li et al.2019|The potential application of spring Sargassum glaucescens extracts in the moisture-retention of keratinocytes and dermal fibroblast regeneration after UVA-irradiation
    Olariu et al.2007|Deuterium depleted water–antioxidant or prooxidant
    CN110218756B|2021-04-02|Method for extracting selenium-rich sturgeon bone peptide with anti-aging effect and product
    Ebrahimi et al.2017|Investigating the anti-apoptotic effect of sesame oil and honey in a novel nanostructure form for treatment of heart failure
    WO2016207411A1|2016-12-29|A highly concentrated seawater mineral extract and uses thereof
    Imen et al.2013|Time course of changes in fatty acid composition in the osmoregulatory organs of the thicklip grey mullet | during acclimation to low salinity
    CN106962931B|2020-11-27|Horseradish algae intracellular fluid and preparation method and application thereof
    Ionescu et al.2007|Modulation by quercetin of the effect of certain Hofmeister anions on artificial lipid bilayers
    FR3054133B1|2019-08-16|COSMETIC COMPOSITIONS COMPRISING BIOMINERAL COMPOUNDS AND CORRESPONDING USES FOR SKIN PROTECTION AGAINST ULTRAVIOLET RADIATION
    Sebij et al.2021|Medical compliance. Analysis of trends in research
    FR3049190B1|2019-07-26|CONCENTRATED WATER ENRICHED WITH NATURAL ORTHOSILICIC ACID
    Melnikova et al.2021|The Effect of Betulin Diphosphate in Wound Dressings of Bacterial Cellulose-ZnO NPs on Platelet Aggregation and the Activity of Oxidoreductases Regulated by NAD |+/NAD | H-Balance in Burns on Rats
    AU2015101912A4|2019-05-16|Uses of multipolar microkinetic drinking water in preparing drink, healthcare product or medicament used for combating fatigue
    同族专利:
    公开号 | 公开日
    WO2017050830A1|2017-03-30|
    FR3041253B1|2019-05-24|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    FR2569536A1|1984-08-30|1986-03-07|Michel Maillols|Biological nutrients|
    FR2777778A1|1998-04-24|1999-10-29|Codif International Sa|Cosmetic products containing mineralized water|
    FR2832902A1|2001-12-03|2003-06-06|Gilbert Georges Dubos|Dietary supplement made from lightly ground spelt grains fermented with spring water and optional sea water|
    FR2918564A1|2007-07-13|2009-01-16|Pacific Creation Soc Par Actio|Use of lipophilic extract of Odontella aurita as cosmetic agent for restructuring or avoiding destructuration of skin and to improve elasticity and tonicity of the skin and/or regeneration of the skin after e.g. dermabrasion|
    ES2343777A1|2009-01-14|2010-08-09|Laboratoires Quinton International S.L|Procedure for collection and pharmaceutical packaging of sea water |
    CN104489528A|2015-01-08|2015-04-08|宋子刚|Seawater bean paste and seawater steamed buns stuffed with sweetened bean paste and preparation method of seawater bean paste|WO2019197532A1|2018-04-12|2019-10-17|Laboratoires Gilbert|Composition derived from seawater, process for obtaining same and use thereof in cosmetic compositions|
    FR3101538A1|2019-10-07|2021-04-09|Action Vitale|Composition of physiological solution containing sea water and glutamine and usable to increase the functional viability of biological tissues and living cells.|
    FR3051668B1|2016-05-24|2020-09-04|Fl Nova|SOURCE WATER IN COMPOSITION FOR TOPICAL USE|
    法律状态:
    2016-09-12| PLFP| Fee payment|Year of fee payment: 2 |
    2017-03-24| PLSC| Search report ready|Effective date: 20170324 |
    2017-09-07| PLFP| Fee payment|Year of fee payment: 3 |
    2018-09-11| PLFP| Fee payment|Year of fee payment: 4 |
    2019-09-09| PLFP| Fee payment|Year of fee payment: 5 |
    2020-06-12| CL| Concession to grant licences|Name of requester: OCEAN HERITAGE LABORATORY, FR Effective date: 20200505 |
    2020-09-10| PLFP| Fee payment|Year of fee payment: 6 |
    2021-08-10| PLFP| Fee payment|Year of fee payment: 7 |
    优先权:
    申请号 | 申请日 | 专利标题
    FR1558879|2015-09-21|
    FR1558879A|FR3041253B1|2015-09-21|2015-09-21|USE OF AN OSMOTIC ISOTONIC ELECTROLYTE SOLUTION AS A CELLULAR LIFE MEDIUM IN A COSMETIC, DERMATOLOGICAL OR NUTRITIONAL COMPOSITION|FR1558879A| FR3041253B1|2015-09-21|2015-09-21|USE OF AN OSMOTIC ISOTONIC ELECTROLYTE SOLUTION AS A CELLULAR LIFE MEDIUM IN A COSMETIC, DERMATOLOGICAL OR NUTRITIONAL COMPOSITION|
    PCT/EP2016/072438| WO2017050830A1|2015-09-21|2016-09-21|Use of an osmotic isotonic electrolyte solution as a cellular living environment in a cosmetic, dermatological or nutritional composition|
    [返回顶部]